Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX009 in Advanced Solid Tumors
NCT04886271Phase 2Completed
- Sponsor
- Hanx Biopharmaceuticals
- Start
- May 2021
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HX009 in solid tumor (advanced stage), sponsored by Hanx Biopharmaceuticals. Started May 2021; status: completed.
02
Drugs
HX009
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04886271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886271.